Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.
about
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelSepticaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin.Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant ratsCapsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.Extracellular structure of polysialic acid explored by on cell solution NMR.Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C.Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes.Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.
P2860
Q33602953-78117F28-4B28-4E8A-8A78-D72267F3DAD3Q33984976-06D30EE0-E09D-424F-A95E-B57DB9473D14Q34602010-79ABAD39-8384-4929-9E29-B291B2C08844Q35518459-D2B5EE0E-2331-43AE-A822-619E3DA7EBCEQ35635880-8B88C126-5A9D-4C93-9DD4-D0521CCF8587Q35868784-A483892B-0546-48CD-B0EF-5210BA038D00Q35946870-31E07038-4166-4E38-B4EA-47A14BAD053BQ36314090-8B718DF7-0017-41DD-B94D-F7B01DC61067Q37075472-617FFA63-22FA-4863-BE9C-D44E7579903EQ37215825-2517339E-070C-4CF3-9CEE-B00A26EB2137Q37362174-127E03E6-28A6-47E2-BC96-5BEE74CC4127Q40025165-9D22506D-4107-4F8E-A84E-9749BB2E25DCQ42173007-24A4DCE1-066A-4963-9603-D90FB97AA767
P2860
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protection by natural human im ...... ment-mediated bacterial lysis.
@ast
Protection by natural human im ...... ment-mediated bacterial lysis.
@en
type
label
Protection by natural human im ...... ment-mediated bacterial lysis.
@ast
Protection by natural human im ...... ment-mediated bacterial lysis.
@en
prefLabel
Protection by natural human im ...... ment-mediated bacterial lysis.
@ast
Protection by natural human im ...... ment-mediated bacterial lysis.
@en
P2093
P2860
P1476
Protection by natural human im ...... ment-mediated bacterial lysis.
@en
P2093
Audun Aase
Elisabeth Wedege
Helena Käyhty
Karin Bolstad
Leena Saarinen
Maija Toropainen
Terje E Michaelsen
P2860
P304
P356
10.1128/IAI.73.8.4694-4703.2005
P407
P577
2005-08-01T00:00:00Z